Bicycle Therapeutics (BCYC)
(Delayed Data from NSDQ)
$22.66 USD
+0.45 (2.03%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $22.60 -0.06 (-0.26%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Bicycle Therapeutics PLC Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 526 | 339 | 439 | 136 | 92 |
Receivables | 24 | 21 | 12 | 15 | 7 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 11 | 9 | 8 | 5 | 5 |
Total Current Assets | 562 | 369 | 459 | 156 | 104 |
Net Property & Equipment | 15 | 19 | 3 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 6 | 8 | 3 | 2 | 2 |
Total Assets | 595 | 411 | 480 | 161 | 110 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 13 | 6 | 3 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 32 | 26 | 14 | 12 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 25 | 20 | 19 | 10 | 1 |
Total Current Liabilities | 70 | 53 | 36 | 23 | 9 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 110 | 41 | 52 | 25 | 5 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 31 | 30 | 30 | 15 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 4 | 3 | 3 | 2 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 224 | 140 | 134 | 66 | 17 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 0 | 0 | 0 | 0 |
Capital Surplus | 883 | 601 | 568 | 250 | 195 |
Retained Earnings | -512 | -331 | -218 | -152 | -101 |
Other Equity | -1 | 0 | -3 | -3 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 371 | 271 | 346 | 95 | 93 |
Total Liabilities & Shareholder's Equity | 595 | 411 | 480 | 161 | 110 |
Total Common Equity | 371 | 271 | 346 | 95 | 93 |
Shares Outstanding | 30.00 | 29.60 | 29.40 | 17.70 | 17.70 |
Book Value Per Share | 12.36 | 9.15 | 11.78 | 5.39 | 5.27 |
Fiscal Year End for Bicycle Therapeutics PLC Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 457 | 526 | 572 | 340 |
Receivables | NA | 39 | 24 | 17 | 58 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 20 | 11 | 14 | 10 |
Total Current Assets | NA | 516 | 562 | 603 | 408 |
Net Property & Equipment | NA | 13 | 15 | 16 | 18 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 6 | 6 | 5 | 12 |
Total Assets | NA | 547 | 595 | 639 | 454 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 7 | 13 | 8 | 5 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 26 | 32 | 34 | 37 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 16 | 25 | 27 | 30 |
Total Current Liabilities | NA | 50 | 70 | 70 | 72 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 98 | 110 | 108 | 115 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 31 | 31 | 31 | 31 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 5 | 4 | 4 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 191 | 224 | 223 | 234 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 1 | 1 | 1 | 0 |
Capital Surplus | NA | 895 | 883 | 875 | 633 |
Retained Earnings | NA | -538 | -512 | -463 | -413 |
Other Equity | NA | -1 | -1 | 3 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 356 | 371 | 416 | 220 |
Total Liabilities & Shareholder's Equity | NA | 547 | 595 | 639 | 454 |
Total Common Equity | 0 | 356 | 371 | 416 | 220 |
Shares Outstanding | 42.70 | 42.70 | 30.00 | 30.00 | 30.00 |
Book Value Per Share | 0.00 | 8.34 | 12.36 | 13.87 | 7.34 |